REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on th...
Sinovac Biotech Ltd. is a China-based biopharma...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
ReWalk Robotics (Nasdaq: RWLK) is an innovative medical device company. We design,...
ReWalk Robotics (Nasdaq: RWLK) is an innovative...
BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...
BioLife Solutions is the leading developer, man...
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
Join the National Investor Network and get the latest information with your interests in mind.